The efficacy of PRMT5 inhibitors in the context of MTAP passenger deletions has been demonstrated in several cancers30,31, suggesting that patients with FUS/EWSR1-TFCP2 sarcoma and CDKN2A/MTAP loss may also benefit from PRMT5 inhibitors, which are currently being tested in clinical trials. The gene discussed is CDKN2A; the disease is sarcoma.